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Background: Ventriculostomy insertion is a common neurosurgical intervention and can be complicated by
ventriculostomy-associated cerebrospinal fluid infection (VAI) which is associated with increased morbidity and mortality.
This meta-analysis was aimed at determining the pooled incidence rate (number per 1000 catheter-days) of VAI.
Methods: Relevant studies were identified from MEDLINE and EMBASE and from reference searching of included studies
and recent review articles on relevant topics. The Newcastle-Ottawa Scale was used to assess quality and risk of bias. A
random effects model was used to pool individual study estimates and 95% confidence intervals (CI) were calculated
using the exact Poisson method. Heterogeneity was assessed using the heterogeneity χ2 and I-squared tests. Subgroup
analyses were performed and a funnel plot constructed to assess publication bias.
Results: There were a total of 35 studies which yielded 752 infections from 66,706 catheter-days of observation. The
overall pooled incidence rate of VAI was 11.4 per 1000 catheter days (95% CI 9.3 to 13.5), for high quality studies the rate
was 10.6 (95% CI 8.3 to 13) and 13.5 (95% CI 8.9 to 18.1) for low quality studies. Studies which had mean duration of EVD
treatment of less than 7 days had a pooled VAI rate of 19.6 per 1000 catheter-days, those with mean duration of 7–10
days had VAI rate of 12.8 per 1000 catheter-days and those with mean duration greater than 10 days had VAI rate of 8
per 1000 catheter-days. There was significant heterogeneity for the primary outcome (p = 0.004, I-squared = 44%) and
most subgroups. The funnel plot did not show evidence for publication bias.
Conclusions: The incidence rate of VAI is 11.4 per 1000 catheter-days. Further research should focus on analysis of risk
factors for VAI and techniques for reducing the rate of VAI.
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External ventricular drains (EVD) or ventriculostomies are
commonly used in neurosurgical patients to monitor and
treat raised intracranial pressure, drain intraventricular blood
and temporarily treat acute hydrocephalus. Ventricu-
lostomies are associated with a range of potential infectious
and non-infectious complications [1]. Whilst rare infectious
complications such as skull osteomyelitis, subdural empy-
ema, brain abscess and distant infection are possible, the
most common and clinically significant infectious complica-
tion is ventriculostomy-associated cerebrospinal fluid (CSF)* Correspondence: ramanan.mahesh@gmail.com
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unless otherwise stated.infection (VAI). The VAI rate in the literature is variable,
with individual studies reporting rates from 1% to 45%
[2-36]. Reviews using non-meta-analytic techniques have
found that 8.8% and 9.5% of patients with ventriculostomies
develop VAI. VAI is associated with increased morbidity and
mortality, longer intensive care unit and hospital stay, and
increased healthcare costs [2,13,31].
Furthermore, there are various clinical dilemmas faced
by physicians caring for patients with ventriculostomies
with regard to prompt diagnosis, investigation and treat-
ment of VAI. Clinical signs such as fever, altered con-
sciousness, nuchal rigidity, emesis and focal neurological
deficits are severely confounded by the primary neuro-
logical insult, treatments directed at preventing secondary
neurological injury (sedation, neuromuscular blockade),
seizures, electrolyte disturbances and non-neurologicalal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 MEDLINE and EMBASE search strategy
1. exp Ventriculostomy/
2. (external adj25 ventricular).tw.
3. (ventricular drain or ventricular catheter).tw.
4. exp Cerebrospinal Fluid Shunts/ or exp
Ventriculoperitoneal Shunt/
5. or/1-4
6. exp Postoperative Complications/ or exp Surgical
Wound Infection/ or exp Bacterial Infections/
7. exp Antibiotic Prophylaxis/
8. exp Cerebral Ventriculitis/ or exp Meningitis/
9. ventriculitis.tw.
10. (cerebrospinal adj25 infection).tw.
11. or/6-10
12. 5 and 10
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or subarachnoid blood, neurosurgical interventions, sys-
temic antimicrobial therapy and antibiotic-impregnated
catheters (AIC). Ventriculostomies, like other devices
inserted through the skin, can become colonized by
skin organisms. Colonization is not necessarily indica-
tive of CSF infection, though CSF cultures may be
positive. These difficulties are reflected in the lack of
consensus definition for VAI, uncertainty regarding the
trigger for empirical antibiotic therapy and the result-
ant wide variations in practice relating to both.
The primary aim of this systematic review and meta-
analysis was to determine the pooled incidence rate of
VAI. Secondary aims were to explore factors (such as
duration of ventriculostomy treatment, age group, CSF
infection definition, CSF culture frequency) associated
with the incidence rate of VAI and to describe the
microbiological findings associated with VAI. This study
was conducted using the PRISMA guidelines for con-
duct of systematic reviews [37].Methods
Selection criteria
All observational studies, both retrospective and
prospective, that reported VAI rate were included.
Randomized controlled trials of interventions were not
included. When duplicate cohorts were identified, the
results from the most recent publication were included
to avoid overlap.
Patients with ventriculostomies were included, regard-
less of age or underlying diagnosis. Patients with intra-
cranial pressure monitors or internalized CSF shunts
were excluded.
Studies that reported VAI rates as infections per 1000
catheter-days and studies where this could be calculated
from published data were included. We anticipated that
various different definitions of VAI would be identified
and all of these definitions were included.Search methods
Relevant studies of all languages were identified from
MEDLINE (1966–2013) and EMBASE (1966–2013) da-
tabases (search strategy in Table 1). The references of all
included studies and relevant reviews [1,38-41] were
searched for additional studies. The literature and
reference search were performed by M.R. in June 2013.
Titles and abstracts were reviewed, and relevant stud-
ies were selected for full text review. Studies which met
the pre-specified inclusion criteria on full text review
were selected for inclusion in the meta-analysis. Reasons
for exclusion were recorded. The full text review was
performed by two authors (M.R. and Ap.S.) with disputes
resolved by discussion.Data collection
A data collection spreadsheet was created in Microsoft
Excel 2010 and data extracted by two authors (M.R. and
Ap.S.). The following data were extracted from each se-
lected study; publication year, country, study type (retro-
spective or prospective), gender, mean age, numbers of
patients, ventriculostomies, catheter-days and VAI’s. The
following data were extracted for subgroup analyses and
secondary objectives; CSF culture frequency, VAI defin-
ition, underlying diagnosis, antibiotics, AIC, duration of
ventriculostomy and microbiological findings.
Quality appraisal
Quality appraisal was conducted using the Newcastle-
Ottawa scale (NOS) [42]. For cohort studies, the NOS is
scored out of nine stars, four for selection, two for com-
parability and three for outcome. For this review, four of
the nine items were relevant (“representativeness of the
exposed cohort”, “demonstration that outcome of inter-
est not present at start of study”, “assessment of out-
come” and “adequacy of follow-up”). We defined studies
that scored zero to two stars as low quality, and studies
that scored three or four stars as high quality for sensi-
tivity analysis purposes.
Statistical analysis
The outcome of interest was incidence rate of VAI per
1000 catheter-days. 95% confidence intervals (CI) were
calculated for individual studies using an exact Poisson
method in Statistical Analysis Software 9.2 (SAS, Cary,
NC, USA) with PROC GENMOD. The meta-analysis
was performed in Microsoft Excel 2010 [43] using the
random effects method [44] to determine the pooled in-
cidence rate. Forest plots were created to provide visual
representation of the data and were inspected for het-
erogeneity. For objective measures of heterogeneity, the
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A significance threshold of p = 0.05 was applied to the het-
erogeneity χ2. I-squared values less than 25% were defined
as low heterogeneity, 25-50% as moderate and greater
than 50% as high heterogeneity.
Pre-specified subgroup analyses were performed to
test the effect of study type (retrospective versus prospect-
ive), AIC usage, infection definition, culture frequency,
publication year, age group and duration of ventriculost-
omy insertion on the incidence rate of VAI. Sensitivity
analysis was performed by examining the effect of remov-
ing small studies (defined as 1000 catheter-days or less)
and low quality studies (defined as one or two stars on the
Newcastle-Ottawa scale). A funnel plot [46] was examined
for evidence of publication bias.
Results
Literature search
5219 studies were identified in our search (Figure 1).
3314 were in MEDLINE, 1893 in EMBASE and 12 in
the reference search. Out of these, 76 were chosen for
full text review from which 35 met pre-specified inclu-
sion criteria and were included in the meta-analysis.
Study characteristics
The 35 included studies (Table 2) yielded 752 VAI’s from
66,707 catheter-days. There were 6681 patients from 33
studies in which this information was available. Different
definitions of VAI were used across the selected studies.
The two most common definitions were positive culture
in 18, the Centre for Disease Control (CDC) definition
[47] in five studies. Of the remaining 12 studies, five
used positive culture plus clinical or other microbiologicalFigure 1 Flow diagram of the search strategy and exclusions at eachcriteria and seven used positive culture or clinical or
microbiological criteria to define VAI. AIC were used in
four studies (33% to 100% of patients) and were not used
in 18 with AIC information unavailable in the remaining
13. Patient characteristics from individual studies are pre-
sented in Table 2.
Quality appraisal
The quality of selected studies was assessed using four
items from the NOS (Table 3). 11 studies met all criteria
and scored four “stars” whilst 13 scored three, eight
studies scored two and three scored one star. No studies
scored zero stars. 31 studies scored a star for adequacy
of follow-up, 26 for representativeness of the cohort, 24
for assessment of outcome and 21 for demonstration
that VAI was not present at the outset.
Main results
Incidence
The 95% CI’s for the individual study estimates are
shown on the forest plot (Figure 2). The pooled VAI rate
(Figure 2) was 11.4/1000 catheter-days (95% CI 9.3 to
13.5). Significant heterogeneity was detected using the
heterogeneity χ2 test (χ2 = 60.19, degrees of freedom
(df ) = 34, p = 0.004). The I-squared test (I-squared =
45%) was consistent with moderate heterogeneity.
Microbiology
There were a total of 523 positive cultures from 25 studies
which presented microbiological data (Figure 3). 333(64%)
of these were gram positive bacteria, 177(35%) gram nega-
tive bacteria and 6(1%) were Candida spp., 95 were
Staphylococcus epidermidis, with another 105 reported asstage.
Table 2 Characteristics of included studies





Males (%) Trauma (%)
Alleyne [31] 2000 USA Retrospective 308 - 9.3 46.6 50.6 27.9
Arabi [36] 2005 Saudi
Arabia
Retrospective 84 99 7 34 78.6 63.1
Bota [35] 2005 Belgium Retrospective 638 - 9.5 41.3 56.9 23
Camacho [8] 2011 Brazil Prospective 119 130 7.1 44.4 48.7 26.9
Chi [24] 2009 Taiwan Retrospective 155 197 18.8 58.1 63.2 -
Dasic [10] 2006 UK Retrospective 95 113 10.7 54.7 62.1 -
Fichtner [28] 2010 Germany Retrospective 164 - 10 53.5 50 -
Hader [17] 2000 Canada Retrospective 157 160 5.6 8 0 40.8
Hoefnagel [2] 2008 Netherlands Retrospective 228 - 8.1 58 49.6 3.5
Holloway [25] 1996 USA Retrospective 584 866 7.5 29.9 77.2 100
Khalil [9] 2005 UK Retrospective . 24 12.3 - - -
Kim [34] 2012 USA Retrospective 343 - 12.4 53.7 42 -
Kitchen [6] 2011 UK Retrospective 133 195 7.1 55 35.3 -
Lemcke [20] 2012 Germany Retrospective 95 95 13.7 53.6 53.7 10.5
Leverstein Van-Dall [21] 2010 Netherlands Retrospective +
Prospective
. 363 9.2 - - -
Lo [18] 2007 Australia Retrospective 199 269 8.2 41 64 74
Lundberg [16] 2000 Sweden Prospective 157 157 7.4 - - 24.8
Lwin [27] 2012 Singapore Retrospective +
Prospective
234 - 7.8 - 65 -
Lyke [13] 2001 USA Retrospective 157 196 5.3 54.5 42.7 0
Mahe [7] 1995 France Retrospective 53 64 14.6 47.3 - -
McLaughlin [19] 2012 USA Retrospective 75 97 13.7 59 34.7 0
Moon [12] 2007 Korea Retrospective 112 174 8.3 48.5 63.4 63.4
Park [29] 2004 USA Retrospective 595 770 8.6 51.3 51.3 12.6
Rafiq [15] 2011 Pakistan Retrospective 76 - 11.4 37.9 53.9 -
Rivero-Garvia [26] 2011 Spain Retrospective 534 648 10.2 - - -
Roitberg [30] 2001 USA Retrospective 103 - 10.7 - 39.8 2.9
Scheithauer [23] 2009 Germany Prospective 225 - 11.2 - - -
Scheithauer [22] 2010 Germany Prospective 158 - 14.3 - - -
Schodel [32] 2012 Germany Retrospective 166 - 17.1 58.7 44 9
Schultz [11] 1993 USA Prospective 78 94 11.9 48.8 53.8 37.2
Sloffer [33] 2005 USA Retrospective 100 113 11.4 55.6 39 8
Smigoc [5] 2012 Slovenia Retrospective 48 - 9.8 - - -
Smith [4] 1976 USA Retrospective 56 65 4 - - -
Williams [14] 2011 Australia Retrospective +
Prospective
382 - 5.4 46.1 60.2 32.2
Wyler [3] 1972 USA Retrospective 70 102 5 7.2 - 0
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Table 2 Characteristics of included studies (Continued)







Culture frequency Infection definition
50.3 21.8 0 100 67.9 twice weekly culture
21.4 15.5 - 59.6 - when indicated culture or wccc +
glucose + clinical
signs
62.2 14.7 0 100 - daily culture + csfd + clinical
53.8 19.3 0 73.1 - when indicated unclear
- - - 100 - when indicated culture
- - 0 - - unclear culture
56.1 - 0 67.7 0 thrice weekly culture
7.6 51.6 0 100 43 daily culture + gram stain
or multiple cultures
78.1 18.4 0 35.5 - thrice weekly culture
0 0 - - - when indicated culture or wcc or csf
glucose
- - - - - unclear culture
71 - 0 100 0 when indicated culture
- - 0 - - unclear culture
83.2 6.3 32.6 100 0 tenth daily culture
- - - - - unclear cdc definition
26 0 0 - - thrice weekly cdc definition
51 24.2 0 - - when indicated or
at removal
culture
- - 0 - - when indicated culture
0 100 100 100 when indicated culture + wcc or
glucose for low
virulence organisms
- - - - - daily culture or wcc
100 0 100 - - when indicated cdc definition
26.8 9.8 - 100 100 daily culture + fever
66.7 20.7 - 100 100 when indicated culture
- - 0 100 100 when indicated culture
- - 42.8 - - when indicated unclear
85.4 11.7 - - - daily clinical + wcc
- - 0 0 0 when indicated cdc definition
- - 0 0 0 thrice weekly cdc definition
86.1 4.8 0 100 0 unclear culture + clinical signs
- - 0 - 94.9 unclear culture
72 20 100 100 - when indicated culture
27.1 - - - - unclear culture or clinical
signs
- - 0 95.4 95.4 unclear culture
38 29.8 - - daily retro, third
daily pros
culture
4.3 95.7 0 - 62.9 insertion, withdrawal
and when indicated
culture
aPeriprocedural = antibiotic administered immediately prior to procedure.
bProphylactic = antibiotic administered for 24 hours or more after the procedure.
cwcc = white cell count.
dcsf = cerebrospinal fluid.
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Table 3 Quality appraisal of included studies using Newcastle-Ottawa Scale











Alleyne 2000 [31] * * * *
Arabi 2005 [36] * *
Bota 2005 [35] * * * *
Camacho 2011 [8] * * *
Chi 2009 [24] * * * *
Dasic 2006 [10] * * *
Fichtner 2010 [28] * *
Hader 2000 [17] * * * *
Hoefnagel 2008 [2] * * *
Holloway 1996 [25] *
Khalil 2005 [9] * * * *
Kim 2012 [34] * * * *
Kitchen 2011 [6] * *
Lemcke 2012 [20] * * * *
Leverstein Van-Dall 2010 [21] * *
Lo 2007 [18] * * *
Lundberg 2000 [16] * *
Lwin 2012 [27] * * *
Lyke 2001 [13] * * * *
Mahe 1995 [7] * *
McLaughlin 2012 [19] *
Moon 2007 [12] * * *
Park 2004 [29] * * * *
Rafiq 2011 [15] * * * *
Rivero-Garvia 2011 [26] * *
Roitberg 2001 [30] *
Scheithauer 2009 [23] * * *
Scheithauer 2010 [22] * * *
Schodel 2012 [32] * * *
Schultz 1993 [11] * * *
Sloffer 2005 [33] * * *
Smigoc 2012 [5] * * *
Smith 1976 [4] * *
Williams 2011 [14] * * * *
Wyler 1972 [3] * * *
*Denotes that the quality criteria has been met.
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aureus(of which 12 were methicillin-resistant). Amongst
the gram negative bacteria, Acinetobacter spp.(48) were
the most common, followed by Pseudomonas spp.(31) and
Enterobacter spp.(29). In studies without AIC, 41% (175/
425) of positive cultures were gram negative bacteriawhereas in studies with AIC, 10% (9/83) were gram nega-
tive bacteria.
Sensitivity analysis
Sensitivity analyses (Table 4) were performed using NOS
and sample size criteria. Including only studies with
Figure 2 Forest plot of meta-analysis (random effects model) of ventriculostomy-associated infections. CI confidence interval.
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1000 catheter-days (95% CI 8.3 to 13) with significant
heterogeneity (p = 0.019, I-squared = 41%). The rate was
13.5/1000 catheter-days (95% CI 8.9 to 18.1, heterogen-
eity p = 0.046, I-squared = 46%) when studies with NOSFigure 3 Pie diagram of breakdown of 523 positive cerebrospinal fluiscores of 1 and 2 only were included. With studies hav-
ing sample sizes 1000 catheter-days and under, the VAI
rate was 18.3/1000 catheter-days (95% CI 13.4 to 23.3)
with low, insignificant heterogeneity (p = 0.34, I-squared =
11%). The rate was 9/1000 catheter-days (95% CI 6.8 tod cultures.
Table 4 Subgroup and sensitivity analyses
Comparison n Infections/1000 catheter-days Lower 95% CIa Upper 95% CI p I-squared (%)
Overall 35 11.4 9.3 13.5 0.004 44
Subgroups
Culture frequency
Daily culture 5 10.8 4.8 16.8 0.16 39
Culture when indicated 15 11.2 8.6 13.9 0.16 27
Other culture regimes 15 13.5 9.6 17.4 0.048 41
Infection definition
Culture proven infection 18 11.5 8.4 14.6 0.004 54
CDC definition of infection 5 8.8 6.3 11.3 0.403 0.50
Culture plus other features 5 9.1 4.8 13.4 0.436 0
Culture or other features 7 17 10 24.1 0.347 11
Age group
Paediatric 3 10.6 6.1 15.2 0.429 0
Adult 32 11.5 9.3 13.7 0.002 48
Year
Publication year <2000 5 18.3 12.4 24.3 0.39 3
Publication year 2000+ 30 10.5 8.4 12.6 0.002 47
Duration
Mean duration <7 days 6 19.6 10 24.1 0.6 0
Mean duration 7-10 days 14 12.8 9.5 16 0.03 49
Mean duration >10 days 15 8 5.4 10.5 0.106 37
Study type
Prospective 5 11 6.6 15.4 0.23 29
Retrospective 30 11.4 9.1 13.8 0.003 47
AIC
No AIC 18 10.8 8.1 13.6 0.001 57
Unclear 13 13.7 9.8 17.6 0.19 25
AIC used 4 7.2 2.6 14.1 0.64 0
Sensitivity Analysis
Study size
<=1000 catheter-days 13 18.3 13.4 23.3 0.34 11
>1000 catheter-days 22 9 6.8 11.2 0.027 40
Newcastle-Ottawa score
1 and 2 11 13.5 8.9 18.1 0.046 46
3 and 4 24 10.6 8.3 13 0.019 41
aCI = confidence interval.
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catheter-days were analyzed. Heterogeneity remained sig-
nificant (p = 0.027, I-squared = 40%).
Subgroup analyses
Subgroup analyses (Table 4) were performed based on
age group, publication year, infection definition, study
type, AIC, duration of ventriculostomy insertion and
CSF culture frequency. The studies which defined VAIas positive CSF culture had a pooled VAI rate of 11.5/
1000 catheter-days, those which used the CDC definition
had a rate of 8.8/1000 catheter-days, those which used
positive culture plus other clinical or microbiological
features had a rate of 9.1/1000 catheter-days and those
which used positive culture or other clinical or micro-
biological features had a rate of 17/1000 catheter-days.
Studies which had mean duration of EVD treatment of
less than 7 days had a pooled VAI rate of 19.6/1000
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had VAI rate of 12.8/1000 catheter-days and those with
mean duration greater than 10 days had VAI rate of 8/1000
catheter-days. Studies in which AIC were used had a VAI
rate of 7.2/1000 catheter-days whilst the remaining studies
had a pooled rate of 12.1/1000 catheter-days. Studies pub-
lished earlier than 2000 had a higher VAI rate of 18.3/1000
catheter-days compared to 10.5/1000 catheter-days for
studies published 2000 or thereafter. Prospective and
retrospective studies had similar VAI rates of 11 and
11.4/1000 catheter-days respectively.
Funnel plot
A funnel plot was created by plotting catheter-days versus
VAI rate (Figure 4) and visually inspected for evidence of
publication bias. The funnel plot revealed an excess of
smaller studies with extreme estimates, both high and
low, of VAI rate. There was a paucity of larger studies with
extreme estimates of VAI rate. Both observations were
consistent with low likelihood of publication bias.
Discussion
This meta-analysis of 35 observational studies has
calculated a pooled incidence rate of VAI of 11.4/1000
catheter-days (95% CI 9.3-13.5). This translates to 1 VAI
per 88 catheter-days. This result is a benchmark against
which local practices can be compared. There was,
however, significant heterogeneity for the pooled result
(p = 0.004, I-squared = 44%) and most subgroup ana-
lyses. The reasons for this heterogeneity are numerous
and include variations in definition of VAI, antibiotic
usage, CSF investigation regimes, patient population,
publication year, duration of ventriculostomy insertion,
type of catheter, length of subcutaneous tunnel and poten-
tially other unknown factors that cannot be addressed in
this meta-analysis.
In comparison to previous studies [34,38] which simply
added and averaged percentages to generate an overallFigure 4 Funnel plot of incidence of ventriculostomy-associated cereestimate of VAI rate, we have performed, to our know-
ledge, the first systematic review using validated meta-
analytic techniques to determine the pooled VAI rate from
all published studies. The VAI rate of 11.4/1000 catheter-
days can be used by individual institutions as a benchmark
for comparison with their local VAI rates. The effect of
interventions and changes to local practice can be
quantified and compared using this rate. It can be used
by future individual studies or meta-analyses of inter-
ventions aimed at reducing VAI rate to calculate numbers
needed to treat. Further applications would include health
economic calculations of the cost of VAI and the quantifi-
cation of benefits of reducing the VAI rate [48].
From the 25 studies which reported microbiological
data from 523 positive cultures, 64% of culture positive
infections were caused by gram positive bacteria, pre-
dominantly coagulase negative staphylococci (39%, in-
cluding S. epidermidis) and S. aureus(15%). A minority
of infections (1%) were caused by Candida spp., and the rest
(35%) by gram negative bacteria including Acinetobacter
spp.(9.3%) and Pseudomonas spp.(6%) followed by enteric
organisms. Traditional thinking is that skin flora, predomin-
antly staphylococcal species, which gain entry to the
subarachnoid or intraventricular space through the ventri-
culostomy tract cause VAI. Prophylactic and empirical an-
tibiotics are frequently selected on this basis. Further
research is required to differentiate between risk factors
for gram positive and gram negative VAI, however, our
findings suggest that empirical antibiotic regimes that
are not active against gram negative bacteria will be in-
adequate in about a third of all VAI cases. Furthermore,
Acinetobacter and Pseudomonas species, which are resist-
ant to a broader range of antibiotics than the enteric gram
negatives, were the most common gram negative bacteria.
Smaller studies (<1000 catheter-days) reported a much
higher incidence rate of VAI (18.3/1000 catheter-days)
than larger (>1000 catheter-days) studies (9/1000 catheter-
days). This suggests that sampling error may have biasedbrospinal fluid infection versus catheter-days.
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may be more reflective of the true VAI rate. Subgroup ana-
lyses revealed similar VAI rates when studies were grouped
according to age and culture regime. Some individual
studies have suggested that frequent manipulation of
ventriculostomies is a risk factor for VAI [2,49]. Our
results, however, show very similar rates of VAI (10.8
and 11.2/1000 catheter-days) when comparing studies
that performed daily CSF cultures with clinically indi-
cated CSF cultures. An explanation for this is that ven-
triculostomies are accessed for reasons other than CSF
cultures such as flushing the system when blocked
with blood clots, other diagnostic tests (biochemical,
cytological, immunological) and administering intra-
thecal medications.
Studies published prior to 2000 had a higher VAI rate
(18.3/1000 catheter-days) compared to those published
2000 and thereafter (10.5/1000 catheter-days). This may
be a reflection of the evolution and improvement in
infection control and prevention practices over time.
The use of AIC for prevention of VAI is controversial.
Whilst various analyses [40,41] have suggested a protect-
ive effect, the findings presented by Stevens et al. [50]
have raised doubt as to whether the incidence of VAI is
truly reduced or whether the false negative rate is in-
creased by AIC. Our results show that studies in which
AIC were utilized had a pooled VAI rate of 7.2/1000
catheter-days, considerably lower than 12.1/1000 catheter-
days in studies in which AIC were not used or AIC usage
was unclear. The latter rate is perhaps closer to the true
rate of VAI with confounding by AIC usage removed.
There is no universally accepted definition of VAI, as
evidenced by the various definitions encountered during
this meta-analysis. 18 out of 35 studies defined VAI as
micro-organism growth on CSF culture, and the pooled
VAI rate amongst these was 11.5/1000 catheter-days.
Those that used the CDC definition [47], with or without
minor modifications, had a rate of 8.8/1000 catheter-days,
whilst those that defined infection as positive culture plus
clinical or CSF criteria also had a similar pooled VAI rate
of 9.1/1000 catheter-days. Unsurprisingly, studies with a
broader definition of infection, including positive culture
or clinical features of meningo-ventriculitis, or abnormal
CSF parameters, had a much higher rate of 17/1000
catheter-days. Strict definitions that insist upon positive
CSF culture may miss some VAI when AIC are used as
AIC reduce the chance of a positive culture [50]. Failure
to process CSF in anaerobic media with prolonged incuba-
tion is another cause of negative cultures.
The effect of duration of ventricular catheterization on
VAI rate is controversial [1]. Some institutions practice
mandatory ventriculostomy revision after a certain dur-
ation [25], though mandatory revisions have not been
shown to reduce VAI rate [18]. The evidence for increasedduration causing an increased risk of VAI is conflicting
with some studies suggesting an increasing risk with dur-
ation [3,11,13,25,51,52] longer than 5–7 days, with others
showing no association [4,53-56]. In our analysis, we
found decreasing VAI rate with increasing mean duration
of ventricular catheterization when the studies were
grouped according to duration less than 7 days, 7–10
days and greater than 10 days. The estimates were
19.6, 12.8 and 8 per 1000 catheter-days respectively.
Whilst this is an unadjusted analysis that does not con-
trol for confounders, duration of treatment being a risk
factor for VAI cannot be supported based on this data.
Further, presence or suspicion of VAI will lead to
removal and replacement of the ventricular catheter,
whereas a non-infected catheter will tend to be left in
situ as long as clinically indicated. Therefore, to some
extent, it can be expected that the VAI rate will be
higher amongst catheters with a shorter duration.
The main strengths of this meta-analysis are thorough
literature search(including non-English articles) to identify
all relevant published material, large number of included
studies, large number of catheter-days of observation and
infections and low likelihood of publication bias as de-
tected by the funnel plot. The overall quality of studies, as
assessed by the NOS, was high. Whilst efforts were made
to locate all relevant published studies, unpublished data
were not sought. It is plausible that this may have a signifi-
cant impact on the pooled estimate of VAI rate. It is com-
monplace for institutions to audit their hospital-acquired
infection rates. It is possible that such datasets exist in un-
published documents. This meta-analysis was also limited
by reporting of VAI in formats that were not convertible
to rate per 1000 catheter-days. Most of these studies
expressed VAI as percentage of patients or ventriculos-
tomies. Some causes of heterogeneity were explored in
the subgroup analyses, however in this study, being a
meta-analysis of cohort studies we were limited by the
data that individual studies published.
Future research should focus on addressing the limita-
tions of this meta-analysis, particularly on sourcing un-
published data from around the world, to assess the
impact of this data on the results of our study. Data
reporting in such a format that allows calculation of rate
of events per person-time at risk should be encouraged
as a standard format that allows comparisons across co-
horts and pooling in meta-analyses. Participation in mul-
ticenter ventriculostomy registries should be encouraged
as this will facilitate larger sample sizes, standardized
data collection, exploration of heterogeneity, increased
collaboration between researchers and individual patient
data meta-analysis. A large, prospective observational or
population study is required to confirm the results and
explore the reasons for heterogeneity presented in this
review. Further analyses of risk factors, as well as
Ramanan et al. BMC Infectious Diseases  (2015) 15:3 Page 11 of 12identification of preventative measures for VAI could
be addressed in such a study.
Conclusion
Ventriculostomies are common neurosurgical interven-
tions frequently complicated by CSF infection. This meta-
analysis has found that the VAI rate is 11.4/1000 catheter-
days, or 12.1/1000 catheter-days with AIC removed. The
rates across different age groups, study types, CSF culture
regimes and common VAI definitions were similar, whilst
being lower amongst studies with longer mean duration of
ventriculostomy treatment and with AIC usage. The ma-
jority of positive cultures were gram positive bacteria, but
35% of positive cultures were gram negatives, the most
common being Acinetobacter and Pseudomonas species,
with subsequent implications for empirical antibiotic ther-
apy. Future directions include more rigorous analysis of
risk factors for VAI and confirmation of these data with
large prospective, observational studies.
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